Advertisement
Advertisement

ADMA

ADMA logo

ADMA Biologics, Inc.

8.17
USD
Sponsored
-0.30
-3.54%
May 08, 16:00 UTC -4
Closed
exchange

After-Market

8.27

+0.10
+1.20%

ADMA Biologics, Inc. Profile

About

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey.

Info & Links

CEO

Adam S. Grossman

Headquarters

465 STATE ROUTE 17
RAMSEY, NJ 07446, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.admabiologics.com

Auditor

KPMG LLP

Share holders

7

Employees

647

ADMA Biologics, Inc. Statistics

Valuation Measures

Market Capitalization2

1.92B

Enterprise Value

1.98B

Enterprise Value/EBITDA(ttm)

8.88

Price to Earnings Ratio(ttm)

15.29

Price to Sales(ttm)

4.64

Price to Book(mrq)

4.95

Price to Cash(ytd)

15.20

Profitability

Gross Margin(ttm)

57.12%

Operating Margin(ttm)

30.90%

Profit Margin(ttm)

28.53%

Return on Equity(ttm)

37.52%

Return on Invested Capital(ttm)

29.09%

Return on Assets(ttm)

27.87%

Income Statement

Revenue(ttm)

509.86M

Revenue Per Share(ttm)

2.20

Gross Profit(ttm)

312.42M

EBITDA(ttm)3

223.38M

Net Income Available to Common(ttm)

165.35M

Diluted EPS(ttm)

0.60

Share Statistics

Beta (5Y Monthly)

0.82

52-Week Change

-61.46%

S&P 500 52-Week Change

26.60%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

231.77M

Dividend Yield

0.00%

Float4

229.82M

% Held by Insiders

3.50%

% Held by Institutions

75.68%

Balance Sheet

Total Cash(mrq)

138.15M

Total Cash Per Share(mrq)

0.60

Total Debt(mrq)

204.41M

Total Debt/Equity(mrq)

16.74%

Current Ratio(mrq)

6.71%

Quick Ratio(mrq)

3.74%

Book Value Per Share(mrq)

2.01

Cash Flow

Operating Cash Flow Per Share(ytd)

0.21

Free Cash Flow(ytd)

27.82M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement